// App-Quantinova.ai

2127 : Identification of a novel NAMPT inhibition resistance mechanism utilizing the de novo NAD+ biosynthesis pathway

Researchers

Presenter

  • jun guo

Principal Investigators

  • Chris Tse

  • William N. Pappano

Medical Centers

  • AbbVie, Inc., North Chicago, IL

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Fibroblastic sarcoma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Nicotinamide

  • Cysteine Hydrochloride

  • L-Tyrosine

  • GMX1778

  • HT-1080

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved